培养强效抑制剂类药物——Elvitegravir和Dolutegravir。

C. Hicks
{"title":"培养强效抑制剂类药物——Elvitegravir和Dolutegravir。","authors":"C. Hicks","doi":"10.1056/AC201112300000010","DOIUrl":null,"url":null,"abstract":"Four years have passed since the licensing of the first HIV integrase inhibitor, raltegravir, and the drug has proven to be both effective and well","PeriodicalId":88277,"journal":{"name":"Journal watch. AIDS clinical care","volume":"93 1","pages":"5-6"},"PeriodicalIF":0.0000,"publicationDate":"2011-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Growing the intense inhibitor class--Elvitegravir and Dolutegravir.\",\"authors\":\"C. Hicks\",\"doi\":\"10.1056/AC201112300000010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Four years have passed since the licensing of the first HIV integrase inhibitor, raltegravir, and the drug has proven to be both effective and well\",\"PeriodicalId\":88277,\"journal\":{\"name\":\"Journal watch. AIDS clinical care\",\"volume\":\"93 1\",\"pages\":\"5-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-12-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal watch. AIDS clinical care\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1056/AC201112300000010\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal watch. AIDS clinical care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1056/AC201112300000010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

自首个HIV整合酶抑制剂雷替格拉韦(raltegravir)获得许可以来,已经过去了四年,该药物已被证明既有效又良好
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Growing the intense inhibitor class--Elvitegravir and Dolutegravir.
Four years have passed since the licensing of the first HIV integrase inhibitor, raltegravir, and the drug has proven to be both effective and well
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信